Soluble epoxide hydrolase: A new target for cardioprotection

Current Opinion in Investigational Drugs

Volumn 10, Issue 3, 2009, Pages 253-258

  Gross, G J ^a   Nithipatikom, K ^a  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

Coronary heart disease; Cytochrome P450; Heart disease; Ischemia; Pharmacology

Indexed keywords

1 ADAMANTAN 1 YL 3 [5(2(2 ETHOXYETHOXY)ETHOXY)PENTYL]UREA; 12 (3 ADAMANTAN 1 YL UREIDO) DODECANOIC ACID; 12 (3 ADAMANTAN 1 YL UREIDO) DODECANOIC ACID BUTYL ESTER; 14,15 EPOXYEICOSA 5(Z)ENOIC ACID; 2 MORPHOLINO 8 PHENYLCHROMONE; 5 HYDROXYDECANOIC ACID; ARACHIDONIC ACID; CARDIOVASCULAR AGENT; CYTOCHROME P450; EPOXIDE HYDROLASE; EPOXYICOSATRIENOIC ACID; GLIBENCLAMIDE; ICOSANOID; LIPOXYGENASE; PAXILLINE; PROSTAGLANDIN SYNTHASE; UNCLASSIFIED DRUG; WORTMANNIN;

ARACHIDONIC ACID METABOLISM; DOSE RESPONSE; DRUG TARGETING; EXPERIMENTAL ANIMAL; GENE DELETION; HEART ARREST; HEART FAILURE; HEART INFARCTION SIZE; HEART MUSCLE CONTRACTILITY; HEART PROTECTION; HEART VENTRICLE HYPERTROPHY; ISCHEMIA; ISCHEMIC HEART DISEASE; NONHUMAN; REPERFUSION INJURY; RESUSCITATION; REVIEW;

ADAMANTANE; ANIMALS; CARDIOMEGALY; CARDIOTONIC AGENTS; CORONARY DISEASE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DESIGN; EICOSANOIDS; ENZYME INHIBITORS; EPOXIDE HYDROLASES; HEART ARREST; HUMANS; LAURIC ACIDS; MICE; MICE, KNOCKOUT; MYOCARDIAL CONTRACTION; MYOCARDIAL INFARCTION; UREA;

EID: 62249094669     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (25)

1. Rosamond W, Flegal K, Friday G, Furie K, Go A, Greenlund K, Haase N, Ho M, Howard V, Kissela B, Kittner S et al: Heart disease and stroke statistics - 2007 update: A report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation (2007) 115(5):e69-e171. • An excellent summary of the demographics of CVD in the US.
2. Murry CE, Jennings RB, Reimer KB: Preconditioning with ischemia: A delay of lethal cell injury in ischemic myocardium. Circulation (1986) 74(5):1124-1136. • The first paper to describe the phenomenon of IPC and the consequent reduction in infarct size in dogs.
3. Zhao ZQ, Corvera JS, Halkos ME, Kerendi F, Wang NP, Guyton RA, Vinten-Johansen J: Inhibition of myocardial injury by ischemic postconditioning during reperfusion: Comparison with ischemic preconditioning. Am J Physiol Heart Circ Physiol (2003) 285(2):H579-H588. • The first paper to describe the phenomenon of ischemic postconditioning during reperfusion and compare its efficacy with that of ischemic IPC.
4. Spector AA, Norris AW: Action of epoxyeicosatrienoic acids on cellular function. Am J Physiol Cell Physiol (2007) 292(3):C996-C1012. • A thorough review of the cellular actions of the EETs in different organs.
5. Granville DJ, Tashakkor B, Takeuchi C, Gustafsson AB, Huang C, Sayen MR, Wentworth P Jr, Yeager M, Gottlieb RA: Reduction of ischemia and reperfusion-induced myocardial damage by cytochrome P450 inhibitors. Proc Natl Acad Sci USA (2004) 101(5):1321-1326.
6. Gross GJ, Hsu A, Falck JR, Nithipatikom K: Mechanisms by which epoxyeicosatrienoic acids (EETs) elicit cardioprotection in rat hearts. J Mol Cell Cardiol (2007) 42(3):687-691.
7. Nithipatikom K, DiCamelli RF, Kohler S, Gumina RJ, Falck JR, Campbell WB, Gross GJ: Determination of cytochrome P450 metabolites of arachidonic acid in coronary venous plasma during ischemia and reperfusion in dogs. Anal Biochem (2001) 292(1):115-124. • The first evidence that EETs are cardioprotective, and that 20-HETE results in a greater degree of injury in canine hearts.
8. Morisseau C, Goodrow MH, Dowdy D, Zheng J, Greene JF, Sanborn JR, Hammock BD: Potent urea and carbamate inhibitors of soluble epoxide hydrolases. Proc Natl Acad Sci USA (1999) 96(16):8849-8854. •• Publication of the first discovery of selective and potent inhibitors of sEHs, including AUDA, and demonstration that these compounds may have anti-inflammatory effects.
9. Siinal CJ, Miyata M, Tohkin M, Nagata K, Bend JR, Gonzalez FJ: Targeted disruption of soluble epoxide hydrolase reveals a role in blood pressure regulation. J Biol Chem (2000) 275(51):40504-40510.
10. Seubert JM, Sinal CJ, Graves J, DeGraff LM, Bradbury JA, Lee CR, Goralski K, Carey MA, Luria A, Newman JW, Hammock BD et al: Role of soluble epoxide hydrolase in postischemic recovery of heart contractile function. Circ Res (2006) 99(4):442-450. •• The first study to demonstrate a cardioprotective effect of knocking-out the sEH gene in mice. sEH null mice demonstrated a greater recovery of contractile function than corresponding wild-type mice, and had a slightly smaller infarct size after 20 min of ischemia, followed by 40 min of reperfusion.
11. Gross GJ, Gauthier KM, Moore JM, Falck JR, Hammock BD, Campbell WB, Nithipatikom K: Effects of the selective EET antagonist, 14,15-EEZE, on cardioprotection produced by exogenous or endogenous EETs in the canine heart. Am J Physiol Heart Circ Physiol (2008) 294(6):H2838- H2844. •• The first study to demonstrate that the inhibition of sEH by AUDA produced a marked and dose-related reduction in infarct size in the canine heart. In the presence of a low-dose of AUDA, 14,15-EET produced a greater reduction in infarct size than either AUDA or 14,15-EET provided when administered alone (an additive effect). In addition, the protective effect of AUDA was blocked by the selective EET antagonist 14, 15-EEZE, which suggests that AUDA was acting via preservation of endogenous EETs.
12. Motoki A, Merkel MJ, Packwood WH, Cao Z, Liu L, Iliff J, Alkayed NJ, Van Winkle DM: Soluble epoxide hydrolase inhibition and gene deletion are protective against myocardial ischemia-reperfusion injury in vivo. Am J Phys Heart Circ Physiol (2008) 295(5):H2128-H2134.
13. Batchu SN, Law E, Brocks DR, Falck JR, Seubert JM: Epoxyeicosatrienoic acid prevents postischemic electrocardiogram abnormalities in an isolated heart model. J Mol Cell Cardiol (2009) 46(1):67-74.
14. Gauthier KM, Deeter C, Krishna UM, Reddy YK, Bondlela M, Falck JR, Campbell WB: 14,15-Epoxyeicosa-5(Z)-enoic acid: A selective epoxyeicosatrienoic acid antagonist that inhibits endothelium-dependent hyperpolarization and relaxation in coronary arteries. Circ Res (2002) 90(9):1028-1036.
15. Gross ER, Hsu AK, Gross GJ: Opioid-induced cardioprotection occurs via glycogen synthase kinase β inhibition during reperfusion in intact rat hearts. Circ Res (2004) 94(7):960-966.
16. Gomez L, Paillard M, Thibault H, Derumeaux G, Ovize M: Inhibition of GSK3β by postconditioning is required to prevent opening of the mitochondrial permeability transition pore during reperfusion. Circulation (2008) 117(21):2761-2768.
17. Nithipatikom K, Moore JM, Isbell MA, Falck JR, Gross GJ: Epoxyeicosatrienoic acids in cardioprotection: Ischemic versus reperfusion injury. Am J Physiol Heart Circ Physiol (2006) 291(2):H537- H542. • The first evidence to suggest that EETs produce benefits on both ischemic and reperfusion injury in a canine model of infarction.
18. Xu D, Li N, He Y, Timofeyev V, Lu L, Tsai HJ, Kim IH, Tuteja D, Mateo RKP, Singapuri A, Davis BB et al: Prevention and reversal of cardiac hypertrophy by soluble epoxide hydrolase inhibitors. Proc Natl Acad Sci USA (2006) 103(49):18733-18738. • The first study to demonstrate that sEH inhibitors can prevent or reverse LVH and abate the arrhythmias that usually accompany cardiac hypertrophy in mice.
19. Monti J, Fischer J, Paskas S, Heinig M, Schulz H, Gösele C, Heuser A, Fischer R, Schmidt C, Schirdewan A, Gross V et al: Soluble epoxide hydrolase is a susceptibility factor for heart failure in a rat model of human disease. Nat Genet (2008) 40(5):529-537.
20. Inceoglu B, Schmelzer KR, Morisseau C, Jinks SL, Hammock BD: Soluble epoxide hydrolase inhibition reveals novel biological functions of epoxyeicosatrienoic acids (EETs). Prostaglandins Other Lipid Mediat (2007) 82(1-4):42-49. • A concise review of the results of inhibiting sEH by gene knockout or with selective pharmacological inhibitors in different organ systems, and their potential as therapeutic agents in various diseases.
21. Imig JD: Cardiovascular therapeutic aspects of soluble epoxide hydrolase inhibitors. Cardiovasc Drug Rev (2006) 24(2):169- 188.
22. Harris TR, Li N, Chiamvimonvat N, Hammock BD: The potential role of soluble epoxide hydrolase in the treatment of cardiac hypertrophy. Congest Heart Fail (2008) 14(4):219-224.
23. Hutchens MP, Nakano T, Dunlap J, Traystman RJ, Hurn PD, Alkayed NJ: Soluble epoxide hydrolase gene depletion reduces survival after cardiac arrest and cardiopulmonary resuscitation. Resuscitation (2008) 76(1):89-94.
24. Newman JW, Morisseau C, Harris TR, Hammock BD: The soluble epoxide hydrolase encoded by EPHX2 is a bifunctional enzyme with novel lipid phosphate phosphatase activity. Proc Natl Acad Sci USA (2003) 100(4):1558-1563.
25. Miura T, Miki T: Limitation of myocardial infarct size in the clinical setting: Current status and challenges in translating animal experiments into clinical therapy. Basic Res Cardiol (2008) 103(6):501-513.